Vertex Pharmaceuticals Inc.VRTX
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NASDAQ · United States · vrtx.com
Vertex Pharmaceuticals Incorporated is a global biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing medicines for serious diseases. The company is a leader in cystic fibrosis treatment with approved therapies including TRIKAFTA/KAFTRIO, and is headquartered in Boston, Massachusetts.
Key ratios
Operating cash flow growth
11.6%TTM
2023
-14.4%
EPS growth
22.1%TTM
2023
8.4%
FCF / Sales
30.2%TTM
2025
26.6%2024
-7.2%2023
33.8%
Net margin
35.0%TTM
2025
32.9%2024
-4.9%2023
36.7%
ROA
11.9%TTM
2025
12.2%2024
12.1%2023
13.2%
ROE
23.5%TTM
2025
22.5%2024
-3.2%2023
23.0%
Revenue growth
10.2%TTM
2025
8.9%2024
11.7%2023
10.5%
Recent news
Vertex Signs Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance for ALYFTREK for the Treatment of Cystic Fibrosis
Vertex Presents New Data on CASGEVY®, Including First European Presentation of Data in Children Ages 5–11, at the European Hematology Association Congress and Announces Additional Global Regulatory Submissions
Vertex Announces US FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA Nephropathy
Track VRTX in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer